NICE updates guidance on 7 DMARDS for rheumatoid arthritis
In final updated guidance NICE recommends a number of drugs (DMARDs) as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs. The guidance does not recommend their use for treating moderate active rheumatoid arthritis. The guidance recommends Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Pfizer, Remicade (infliximab) from Merck Sharp & Dohme; Inflectra, Hospira and Remsima from Napp Pharmaceuticals), Cimzia (certolizumab pegol) from UCB Pharma, Simponi (golimumab) from Merck Sharp & Dome, RoActemra (tocilizumab) from Roche and Orencia (abatacept) from Bristol-Myers Squibb, each in combination with methotrexate. Adalimumab, etanercept, certolizumab pegol or tocilizumab are also recommended as monotherapy for people who cannot take methotrexate.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins